Volume 6 Supplement 1
15th Paediatric Rheumatology European Society (PreS) Congress
Meeting abstracts
Edited by Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott
15th Paediatric Rheumatology European Society (PreS) Congress. Go to conference site.
London, UK14-17 September 2008
Page 2 of 7
-
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S26
-
MEFV mutations in systemic JIA
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P26 -
13.4 High frequency of CNS involvement in linear scleroderma of the face
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S27 -
Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P27 -
14.1 Clinical spectrum and outcome in 100 children with positive antiphospholipid antibodies
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S28 -
Gene expression in active systemic JIA after anti-IL1 and anti-IL6R treatment
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P28 -
14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S29 -
Early effects of Anakinra in corticosteroid naïve SOJIA patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P29 -
14.3 Early cardiovascular risk assessment in patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S30 -
Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P30 -
14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S31 -
A phenotypic shift after initiation of IL-1 receptor blockade in a boy with systemic juvenile arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P31 -
14.5 Rheumatoid Arthritis susceptibility loci; STAT4, TRAF1/C5 and 6q23 region, are also associated with Juvenile Idiopathic Arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S32 -
Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P32 -
14.6 MRP-Targeting in experimental rheumatoid arthritis allows monitoring of disease activity with optical molecular imaging
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S33 -
Macrophage activation sydrome with systemic onset juvenile idiopathic arthritis (SOJIA) in Chinese childern
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P33 -
15.3 Agreement between parent and adolescent assessment of disability, pain and well-being: results from the Childhood Arthritis Prospective Study (CAPS)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S34 -
The TLR4 ligands MRP8 and MRP14 in the diagnosis and pathogenesis of systemic onset juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P34 -
Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P35 -
Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P36 -
Efficacy and safety of anti-TNF agents in patients with enthesitis related arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P37 -
DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P38 -
Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P39 -
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P40 -
Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P41 -
Juvenile Psoriatic Arthritis (JPsA) clinical features and outcome of 119 patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P42 -
Mandibular condyle destruction in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P43 -
Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P44 -
Relationship between delayed menarche and bone density in patients affected by juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P45 -
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P46 -
Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P47 -
Use of Intravenous Immunoglobulin Therapy in a paediatric rheumatology service
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P48 -
A safe protocol for tuberculin test assessment in a country where BCG vaccination is mandatory
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P49 -
Growth retardation in patients with juvenile idiopathic arthritis and growth hormone therapy
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P50 -
Sleep, fatigue and quality of life in juvenile idiopathic arthritis (JIA) and Juvenile Dermatomyositis (JDM)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P51 -
Illness representation in adolescents with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P52 -
Hip arthritis in the TNF-Blockade era: an unresolved issue?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P53 -
Arthritis in Down's syndrome is still being missed
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P54 -
Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P55 -
Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P56 -
HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P57 -
Does unity of Familial Mediterranean fever with juvenile idiopathic arthritis affect the outcome?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P58 -
Association between inflammatory status and intima-media-thickness in children with juvenile idiopathic arthritis: preliminary data
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P59 -
Performance of IFN-Gamma release assays for detection of tuberculosis infection in juvenile I JIA children in biological therapy
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P60 -
Anti-cyclic citrullinated peptide: its prevalence and clinical significance in a South African cohort with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P61 -
Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P62 -
Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P63 -
The therapeutic value of low-energy laser (LLLT) for enthesitis in children with juvenile spondyloarthropathies
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P64 -
Methotrexate shows the same efficacy and safety in the real world in all subtypes of JIA as in the controlled trial
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P65 -
Bone mass predictors in a large cohort of children with juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P66
Official journal of
Annual Journal Metrics
-
2022 Citation Impact
2.5 - 2-year Impact Factor
3.0 - 5-year Impact Factor
1.035 - SNIP (Source Normalized Impact per Paper)
0.732 - SJR (SCImago Journal Rank)2023 Speed
18 days submission to first editorial decision for all manuscripts (Median)
94 days submission to accept (Median)2023 Usage
1,095,144 downloads
691 Altmetric mentions